8-K current report · filed Jul 6, 2026

RxSight, Inc. (RXST) 8-K Current Report: July 6, 2026

Item 1.01Item EX-99.1Item 7.01RXST overview

Short answer

RxSight, Inc. (RXST) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Alcon collaboration adds $60M upfront cash and potential $140M milestone payments tied to feasibility, FDA submission, and approval.

RxSight, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Alcon collaboration adds $60M upfront cash and potential $140M milestone payments tied to feasibility, FDA submission, and approval
  • 30% royalties on net Collaboration Product sales, with minimum royalty obligations and customary adjustments
  • RxSight retains U.S. regulatory approvals and will exclusively manufacture products, creating supply and service revenue opportunities
  • Alcon leads commercialization after approval, targeting U.S. launch within one year and potentially adding global commercial reach
  • Development restrictions could reduce royalties by 60% or more and require partial payment reimbursement if RxSight pursues competing SVIOLs

Item 7.01 · Regulation FD Disclosure

  • RxSight-Alcon Collaboration Agreement announced on July 6, 2026, establishing a strategic partnership
  • Potential milestone payments and royalties create future revenue opportunities for RxSight
  • Collaboration benefits depend on technology transfer, manufacturing execution and regulatory approvals
  • Commercial success remains uncertain, with execution risks tied to third-party collaboration and new product development

Item EX-99.1 · Exhibit EX-99.1

  • Non-exclusive Alcon collaboration expands RxSight’s light-adjustable technology into presbyopia-correcting lenses
  • $60 million upfront payment provides near-term development funding
  • Up to $140 million in additional milestone payments, contingent on development and regulatory progress
  • RxSight retains development and manufacturing, with royalties on net sales
  • Alcon leads global commercialization, offering RxSight broader market access but less commercial control

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other RxSight, Inc. 8-K filings

Get the next RXST 8-K as it lands

Follow RXST for push alerts, or ask the research agent what this filing means.